We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Ponders New Approach for Opioid Risk-Benefit Assessments
FDA Ponders New Approach for Opioid Risk-Benefit Assessments
Opioid sponsors would have to prove that their drug candidates are better than currently approved drugs under new guidelines that the FDA is considering, the agency announced Thursday.